Most of these agents in development offer limited clinical benefit over existing treatments, with 82% of the recently approved antibiotics being derivatives of existing antibiotic classes with well-established drug-resistance.
14113
因此，预计对这些新药剂的耐药性将迅速出现。
Therefore, rapid emergence of drug-resistance to these new agents is expected.
The review concludes that “overall, the clinical pipeline and recently approved antibiotics are insufficient to tackle the challenge of increasing emergence and spread of antimicrobial resistance”.
14115
传统开发途径之外新的解决方案
Novel solutions outside the traditional development pathway:
14116
抗生素开发缺乏进展，凸显了需要探索治疗细菌感染的创新方法。
The lack of progress on antibiotic development highlights the need to explore innovative approaches to treat bacterial infections.
14117
世卫组织2020年开发情况报告首次全面概述了非传统抗菌药物。
The 2020 WHOpipeline report for the first time includes a comprehensive overview of non-traditional antibacterial medicines.
It highlights 27 non-traditional antibacterial agents in the pipeline ranging from antibodies to bacteriophages and therapies that support the patient’s immune response and weaken the effect of the bacteria.
14119
高失败率和对市场动态的影响
High failure rates and impact on market dynamics:
14120
报告指出，在不同的开发阶段都有一些有希望的产品。
The report notes that there are some promising products in different stages of development.